Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression in p...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2019-12-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	pancreatic cancer tyrosine kinase inhibitors RON receptor tyrosine kinase MET receptor tyrosine kinase prognosis biomarker therapeutic target
Online-Zugang:	https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!